Clinical Trials Industry News More

  1. Researchers Test Inhalable Measles Vaccine 2/1/2011
    Sustained high vaccination coverage is key to preventing deaths from measles. Despite the availability of a vaccine,
  2. BioClinica Partners With Symbiance 1/25/2011
    BioClinica, Inc.,a global provider of clinical trial management solutions, recently announced it has established a strategic partnership with Symbiance Inc., a specialty contract research organization (CRO) based in Princeton Junction, New Jersey. Symbiance concentrates in therapeutic areas relevant to pharmaceutical and biotechnology companies with particular focus in oncology and CNS.
  3. Adamis Pharmaceuticals Announces Phase 3 Meets Primary Endpoint 12/8/2010
    Adamis Pharmaceuticals Corporation announced the successful completion of a Phase 3 contraceptive trial of the company's contraceptive gel product candidate named Savvy® (C31G).
  4. Juvenile Diabetes Research Foundation And Amylin Pharmaceuticals Partner To Investigate Metreleptin As Potential Therapy To Improve Blood Glucose Control In Type 1 Diabetes 11/19/2010
    The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced today that they entered into a research collaboration agreement to provide financial support for a clinical proof-of-concept study to investigate the effects of metreleptin, an analog of the human hormone leptin, in patients with type 1 diabetes. Researchers at The University of Texas (UT) Southwestern Medical Center will conduct the study.
  5. Harbor BioSciences Apoptone® For Prostate Cancer Shows A Partial Overall Response 9/15/2010
    Harbor BioSciences, Inc. (Nasdaq:HRBR) a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.
  6. Plexxikon Publishes PLX4032 Phase 1 Data Demonstrating 81 Percent Response Rate In Metastatic Melanoma Patients In The New England Journal Of Medicine 8/27/2010
    Plexxikon today announced publication of data from the Phase 1 clinical trial of PLX4032 (RG7204), confirming that treatment of metastatic melanoma patients with the BRAF V600E mutation resulted in significant tumor shrinkage in the majority of patients.
  7. Akebia Announces Initiation Of Phase 2a Clinical Study Of AKB-6548 7/22/2010
    Akebia Therapeutics, Inc., a pharmaceutical discovery and development company focused on anemia and vascular disorders, today announced that it has initiated dosing in patients for a phase 2a single dose clinical trial of AKB-6548, an orally bioavailable hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) in development for anemia.
  8. Pennington Biomedical Research Institute And Compellis Pharmaceuticals Complete Phase I Study Of Novel And Patented Obesity Therapy 7/22/2010
    Compellis Pharmaceuticals, Inc., an early-stage pharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity, announced today with its collaborator Pennington Biomedical Research Institute at Louisiana State University, that they have successfully completed a human Phase I pilot clinical trial.
  9. Tekmira's Partner Alnylam Initiates Dosing In A Phase 1 Clinical Trial Of ALN-TTR01 7/8/2010
    Tekmira Pharmaceuticals Corporation (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that one of the company's partners, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) has initiated dosing in a Phase 1 human clinical trial of its product candidate ALN-TTR01.
  10. Infinity Initiates Second Clinical Trial Of IPI-493, Its Oral Hsp90 Chaperone Inhibitor 6/29/2010
    Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that patients are being enrolled in a Phase 1 clinical trial evaluating IPI-493 in patients with advanced hematologic malignancies.